Precigen, Inc.
NASDAQPGEN heads into its August 12 earnings event with a striking divergence: the stock is up 18% on the week and analysts are raising targets, yet C-suite insiders have been selling consistently into every rally. The analyst angle sharpened this week. HC Wainwright lifted its price target on PGEN to $18 from $14 on August 5, keeping its Buy rating, after reiterating the same $14 target…
Snapshot as of 26 Aug 2026
PGEN heads into its August 12 earnings event with a striking divergence: the stock is up 18% on the week and analysts are raising targets, yet C-suite insiders have been selling consistently into every rally. The…
PGEN heads into its June 18 earnings call with short sellers in an extended retreat — but still holding a position large enough to keep the stock structurally contested. Short interest has fallen from a peak above…
PGEN enters the post-earnings window with an interesting tension: a stock still down 6% on the week, a short position that has been quietly unwinding, and a Q1 revenue beat that confirms Papzimeos is ramping faster…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PGEN — free to start on ORTEX.
Sign up for free →Open PGEN on ORTEX